Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies - Wikidata - wikimedia - TriplyDB

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies

http://www.wikidata.org/entity/Q34075082

about

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

P2860

Q33781162-670CDB62-E8C0-4A8C-8BA5-B06C467074E0 Q35784529-3748F0FA-800F-4267-A57E-1B1782AB90E9

P2860

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies

http://www.wikidata.org/entity/Q34075082

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Reduced-intensity allogeneic t ...... with hematologic malignancies

@ast

Reduced-intensity allogeneic t ...... with hematologic malignancies

@en

Reduced-intensity allogeneic t ...... with hematologic malignancies

@nl

type

label

Reduced-intensity allogeneic t ...... with hematologic malignancies

@ast

Reduced-intensity allogeneic t ...... with hematologic malignancies

@en

Reduced-intensity allogeneic t ...... with hematologic malignancies

@nl

prefLabel

Reduced-intensity allogeneic t ...... with hematologic malignancies

@ast

Reduced-intensity allogeneic t ...... with hematologic malignancies

@en

Reduced-intensity allogeneic t ...... with hematologic malignancies

@nl

P1433

Q34075082-FBB60C56-14E9-482B-9887-A8D750536E5E

P1476

Q34075082-EFE84C57-BB19-4F51-8475-E552F1094044

P2093

Q34075082-015202B5-EE4B-41A7-A4E1-6F4F414F9BD1

Q34075082-287AA601-4FDD-4CF0-B951-241908F77D1B

Q34075082-403CA73F-3CD9-43A5-A8C8-85655E325B49

Q34075082-5CB8EE2D-3DD2-4A0D-B29E-C1A0D42B1BD6

Q34075082-87D06578-4BCC-42D5-A5F7-F2D1331E4B44

Q34075082-9E1F80D0-1A2E-47E1-B6CD-E41D3576164D

Q34075082-A3AFE6F9-9E61-4175-A695-4FAF5851DBC2

Q34075082-A93297B4-D480-4DAA-8C18-16428B25FE88

Q34075082-D0D54F91-8519-46E6-9714-9B6EBDE36717

Q34075082-D3AD890A-82F2-4901-A84C-29FF12A34983

P2860

Q34075082-0CB11877-3523-4263-9F95-A94A3CDA81D4

Q34075082-1BCAD331-E991-4B7A-AC02-8D7194859E99

Q34075082-1CF8A3EF-3D66-42CA-9FA6-2F6547D0602D

Q34075082-26F6445E-C1DF-4370-B6D6-DE9F80CCC4EC

Q34075082-2876F246-7AF5-453E-AD88-4588862E0121

Q34075082-31045BF9-3057-44F8-8F97-9C72A3810082

Q34075082-3264AC2E-1D58-418A-9BAE-A7EA795BEA3B

Q34075082-47B0AAF2-D861-4A43-8795-C9A34BD0119E

Q34075082-683EA779-D4D3-4A79-A55B-95C211A84E64

Q34075082-BCFB7C94-4310-4346-B213-025471E25256

P304

Q34075082-5B684DF0-17D0-4233-8FB9-9B2B8FBD8F21

P31

Q34075082-27D07E4B-7F92-4F2E-8936-CCE217E12578

P356

Q34075082-628A45FE-6641-4CE2-8DBF-5A2EE5D21FE5

P433

Q34075082-1CA47E4C-A84F-4B5D-B93C-EE1134FCCB68

P478

Q34075082-CA70DDE7-9A09-49FB-9A86-29DA62284278

P50

Q34075082-F475C052-2C11-4C94-98D5-3C903BEF04FD

P577

Q34075082-59F93E23-154D-464F-A109-59268B791EE6

P5875

Q34075082-6639A561-C2EA-4022-81F0-5B4D51469B05

P698

Q34075082-AD80D150-2BA9-4949-814F-B3556AED0C0F

P932

Q34075082-15F83CA6-9398-4C0E-B349-8C9C09029A4A

P356

J.BBMT.2013.11.010

P1433

Biology of Blood and Marrow Transplantation

P1476

Reduced-intensity allogeneic t ...... with hematologic malignancies

@en

P2093

Ashley Morris

http://www.w3.org/2001/XMLSchema#string

Cristina Gasparetto

http://www.w3.org/2001/XMLSchema#string

David A Rizzieri

http://www.w3.org/2001/XMLSchema#string

Gwynn D Long

http://www.w3.org/2001/XMLSchema#string

John P Chute

http://www.w3.org/2001/XMLSchema#string

Junya Kanda

http://www.w3.org/2001/XMLSchema#string

Michael Shafique

http://www.w3.org/2001/XMLSchema#string

Mitchell E Horwitz

http://www.w3.org/2001/XMLSchema#string

Nelson J Chao

http://www.w3.org/2001/XMLSchema#string

Zhiguo Li

http://www.w3.org/2001/XMLSchema#string

P2860

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia.

Alemtuzumab for the prevention and treatment of graft-versus-host disease.

Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.

1994 Consensus Conference on Acute GVHD Grading

P304

257-263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2013.11.010

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Keith M. Sullivan

P577

2013-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258853204

http://www.w3.org/2001/XMLSchema#string

P698

24269380

http://www.w3.org/2001/XMLSchema#string

P932

4140655

http://www.w3.org/2001/XMLSchema#string